We write as patients, people with disabilities, caregivers, and the organizations that represent us – people who live every day with serious, chronic, and rare diseases, and who depend on continued medical progress to survive and to thrive. We are urging you to oppose Most Favored Nation (MFN) drug pricing policies that would import foreign prices set using system known to delay and deny patient access, and to instead advance patient-centered solutions that can lower costs without sacrificing American innovation.

Fix Insurance

For decades, the United States has built an internationally respected research enterprise by empowering expert peer review, encouraging collaboration across institutions and disciplines, and providing researchers with the stability needed to pursue difficult scientific questions whose answers may take years to emerge. This system is not perfect and appropriately has built-in levers during the annual appropriations process that allow for accountability, but what we must not overlook is that it has produced extraordinary benefits for patients, taxpayers, and the American economy. The proposed rule would fundamentally alter that model.

This cartoon illustrates how high OOP costs are the branch blocking patients from appropriate medicines, and the fix is to build the bridge: proper insurance with low OOP costs, because that is what makes anything in healthcare affordable for patients.

As a coalition of biotechnology and pharmaceutical innovators, patient advocates, investors, and physicians working at the forefront of science and medicine, we write at this pivotal moment to recommend a leader who can secure and strengthen the U.S. Food and Drug Administration: Dr. Richard Pazdur.

In this series, we’re exploring how we use our defining edge to bring clarity and credibility to policy debates. Most of us pay our health insurance premiums so that if we do get sick or injured, the treatments our doctors prescribe will be covered. But increasingly, that coverage is coming with high out-of-pocket costs.

This cartoon illustrates the value or mortgage payments versus rent, as an analogy for patented drugs that will eventually go generic and drop in price.

This cartoon illustrates the risk of shorter patent windows on continued biopharmaceutical innovation.

For people living with chronic disease, health insurance shouldn’t be another hurdle. We should spend our energy and focus fighting for the best lives we can, not fighting against insurance companies. To learn more about how to #FixInsurance so it works as it should, visit https://www.nopatientleftbehind.org/fixinsurance.

Read our 2025 Impact Report and learn how NPLB continues to champion biotech affordability and innovation.

The newly introduced Lowering Drug Costs for American Families Act1 is framed as a “win” for patients, but it would provide minimal real savings at the pharmacy counter. Instead, it would stall progress on life-saving new cures, increase long-term health spending, and severely weaken Massachusetts’ world-leading life sciences bioeconomy.

While the bill includes helpful out-of-pocket (OOP) caps, it ties them to an expansion of government price-setting that weakens incentives for high-risk medical R&D and harms innovation.

This cartoon illustrates the value produced by the small cost of supporting biopharmaceutical innovation.

This cartoon demonstrates the true value of medicines.

As we indicated in our November 20th letter, No Patient Left Behind (NPLB)'s coalition of biotech investors, innovators, researchers, physicians, and patient advocates is deeply concerned about the direction of the FDA. We further wish to highlight and emphasize the issues raised in the December 3, 2025 Perspective published in the New England Journal of Medicine by twelve FDA commissioner predecessors.

This cartoon illustrates the absurdity of requiring “skin in the game” for life-saving, prescribed medications.

This cartoon simplifies the conversation on vaccines by reminding us of the obvious truth—vaccines are much better than the diseases they prevent.